Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

levalbuterol (Rx)Brand and Other Names:Xopenex, Xopenex HFA

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

nebulizer solution

  • 0.31mg/3mL
  • 0.63mg/3mL
  • 1.25mg/3mL
  • 1.25mg/0.5mL

aerosol

  • 45mcg/actuation
more...

Bronchospasm

Nebulizer solution: 0.63-1.25 mg 3 times daily q6-8hr

Aerosol: 90 mcg (2 actuations of metered-dose inhaler) q4-6hr

Asthma Exacerbation

Nebulizer solution: 1.25-2.5 mg q20min for 3 doses, then 1.25-5 mg q1-4hr PRN

Aerosol: 180-360 mcg (4-8 actuations of metered-dose inhaler) q20min for ≤4 hr, then q1-4hr PRN

Dosage Forms & Strengths

nebulizer solution

  • 0.31mg/3mL
  • 0.63mg/3mL
  • 1.25mg/3mL
  • 1.25mg/0.5mL

aerosol

  • 45mcg/actuation
more...

Bronchospasm

Nebulizer solution

  • <5 years: 0.31-1.25 mg q4-6hr PRN
  • 5-12 years: 0.31 mg q8hr; not to exceed 0.63 mg q8hr PRN
  • >12 years: 0.63-1.25 mg q8hr PRN

Aerosol

  • <4 years: Safety and efficacy not established
  • ≥4 years: 90 mcg (2 actuations of metered-dose inhaler) q4-6hr PRN

Asthma Exacerbation

Nebulizer solution

  • <12 years: 0.075 mg/kg (≥1.25 mg) q20min for 3 doses, then 0.075-0.15 mg/kg (≤5 mg) q1-4hr PRN  
  • ≥12 years: 1.25-2.5 mg q20min for 3 doses, then 1.25-5 mg q1-4hr PRN

Aerosol

  • <4 years: Safety and efficacy not established
  • ≥4 years: 180-360 mcg (4-8 actuations of metered-dose inhaler) q20min for 3 doses, then q1-4hr PRN

Nebulizer solution: 0.63 mg initially in patients >65 years

Next

Interactions

Interaction Checker

levalbuterol and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Headache (8-12%)

            Viral infection (7-12%)

            Rhinitis (3-11%)

            1-10%

            Pharyngitis (3-10%)

            Tremor (7%)

            Sinusitis (1-4%)

            Flu (1-4%)

            Dyspepsia (1-3%)

            Leg cramps (<3%)

            Generalized pain (2.8%)

            Nasal edema (2.8%)

            Nervousness (2.8%)

            Tachycardia (2.8%)

            Postmarketing Reports

            Dysphonia

            Gastroesophageal reflux disease, nausea

            Angioedema, anaphylaxis, rash, urticaria

            Chest pain, tachycardia, arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystoles)

            Asthma, increased cough, dyspnea, dysphonia

            Metabolic acidosis

            Nervousness, tremor

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to levalbuterol or racemic albuterol

            Cautions

            Cardiovascular disorder (eg, arrhythmias, hypertension, coronary insufficiency)

            Risk of paradoxical bronchospasm

            Has higher affinity for beta1- and beta2-adrenergic receptors than racemic albuterol has

            Risk of hypersensitivity reactions

            Use with caution in diabetes mellitus (beta2 agonists may increase glucose)

            Risk of hypokalemia (usually transient)

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Unknown whether drug is excreted in breast milk; discontinue, or do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Beta2-receptor agonist with some beta1 activity; relaxes bronchial smooth muscle

            Absorption

            Onset: Nebulizer solution, 10-17 min; aerosol, 5.5-10.2 min

            Duration: Nebulizer solution, 5-6 hr; aerosol, 3-4 hr

            Peak plasma time (children): Nebulizer solution, 0.3-0.6 hr; aerosol, 0.8 hr

            Peak plasma time (adults): Nebulizer solution, 0.2 hr; aerosol, 0.5 hr

            Time to peak effect: Nebulizer solution, 1.5 hr; aerosol, 77 min

            Elimination

            Half-life: 3-3.4 hr

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.